Conjugated Drug: A New Era in Precision Medicine

Download our Complimentary Blue Book

In recent years, several ADC drugs have achieved sales exceeding 1 billion USD, drawing significant market attention. This rise in ADC drug popularity has driven a wave of innovation in the broader conjugated drug sector, including novel types like RDCs, PDCs, and SMDCs. Increased capital interest and growing clinical demand have positioned conjugated drugs as a focal point in pharmaceutical research.

R

Analysis of the Current Status and Future Trends of ADCs, RDCs, PDCs, and Other Conjugated Drugs

R

Market Performance of Conjugate Drugs

R

Introduction to Selected Companies in the Conjugated Drug Industry: BioDlink, RabPharma, RDO Technology, Escugen Biotech, C Ray Therapeutics, and Duality Biologics

Download Blue Book Now

Download Blue Book Now

"*" indicates required fields

Name*

Job Title*

Company*

Phone*

Business Email*

Country*

Company Size*

CAPTCHA

Comments

This field is for validation purposes and should be left unchanged.

60 YEARS OF INSIGHTS

Our Global Initiatives



Empower innovation, echoing the voices of emerging technologies and companies, shaping progressive pathways in a dynamic market.



Growth Opportunity content distribution to offer a one-stop platform providing a 360-degree global perspective on the latest industry developments, events, and advancements.



Partner to equip your company with insights and enable capitalization on growth opportunities, ensuring your queries are addressed in a global marketplace.

Download Blue Book Now

ABOUT THE ANALYST

Aaron Wang

Project Manager of Frost & Sullivan Greater China, participated in market research projects，focusing on medicine, medical device and medical service.

About Our Firm

Frost & Sullivan

Frost & Sullivan has partnered with clients for more than 60 years, developing growth strategies centered on innovation, disruptive technologies, emerging markets, Mega Trends, and new business models.